Session » (2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2494

Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2492

Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort

10:30AM-12:30PM: Abstract Number: 2471

Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use

10:30AM-12:30PM: Abstract Number: 2476

Blinatumomab in rapid progressive systemic sclerosis

10:30AM-12:30PM: Abstract Number: 2487

Cardiovascular and venous thromboembolic events in systemic sclerosis: Epidemiological analysis of the Clinical Practice Research Datalink

10:30AM-12:30PM: Abstract Number: 2482

Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology

10:30AM-12:30PM: Abstract Number: 2496

Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score

10:30AM-12:30PM: Abstract Number: 2499

Concomitant Anti-Ro/SSA Antibodies in Systemic Sclerosis Patients is Associated with Risks Beyond Dryness

10:30AM-12:30PM: Abstract Number: 2477

Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)

10:30AM-12:30PM: Abstract Number: 2502

Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study

10:30AM-12:30PM: Abstract Number: 2472

Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time

10:30AM-12:30PM: Abstract Number: 2498

Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease

10:30AM-12:30PM: Abstract Number: 2488

Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study

10:30AM-12:30PM: Abstract Number: 2478

Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients

10:30AM-12:30PM: Abstract Number: 2475

GERD Severity, Proton Pump Inhibitor Use, and Longitudinal Forced Vital Capacity in the CONQUER Registry

10:30AM-12:30PM: Abstract Number: 2500

Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 2491

High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study

10:30AM-12:30PM: Abstract Number: 2495

IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation

10:30AM-12:30PM: Abstract Number: 2470

Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2486

In vitro antifibrotic effects of nerandomilast on cell types relevant to intestinal remodeling and fibrosis in systemic sclerosis

10:30AM-12:30PM: Abstract Number: 2493

Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs

10:30AM-12:30PM: Abstract Number: 2483

Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?

10:30AM-12:30PM: Abstract Number: 2501

Microvascular dysfunction contributes to hand bone deterioration in SSc patients

10:30AM-12:30PM: Abstract Number: 2473

Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm

10:30AM-12:30PM: Abstract Number: 2484

Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies

10:30AM-12:30PM: Abstract Number: 2481

Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)

10:30AM-12:30PM: Abstract Number: 2485

Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease

10:30AM-12:30PM: Abstract Number: 2479

REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.

10:30AM-12:30PM: Abstract Number: 2480

Respiratory Muscle Weakness in a Systemic Sclerosis Cohort

10:30AM-12:30PM: Abstract Number: 2490

Unmasking Mortality Risk: The Impact of Systemic Sclerosis in Stress-Induced Cardiomyopathy

10:30AM-12:30PM: Abstract Number: 2489

Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum

10:30AM-12:30PM: Abstract Number: 2497

Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution

10:30AM-12:30PM: Abstract Number: 2474

Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected

10:30AM-12:30PM: Abstract Number: 2503

Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].